MDM2 SNP309 (rs2279744) and p53 Codon Arg72Pro (rs1042522) SNP in Cervical Carcinogenesis

Osamu Nunobiki, Hirohide Sawada, Masatsugu Ueda

Cytopathology and Gynecology, Osaka Center for Cancer and Cardiovascular Diseases Prevention, Osaka, Japan.
Department of Medical Technology, Kobe Tokiwa University, Hyogo, Japan.

DOI: 10.4236/abb.2014.57072                

Abstract

To investigate the association between polymorphisms (SNP) in the p53 and murine double minute 2 homolog (MDM2) promoter 309 in cervical carcinogenesis. SNP at p53 codon 72 polymorphisms and MDM2 promoter 309 (T/G) together with human papillomavirus (HPV) types were examined in a total of 187 cervical smear samples using real time PCR. 27 cases with HPV types 16 and/or 18 had significantly higher frequency of the TG + GG genotype and G allele than 56 with other types of high-risk HPV (P = 0.0136). 48 cases with HPV types 52 and/or 58 had significantly higher frequency of the TG + GG genotype and G allele than 56 with other types of high-risk HPV (P = 0.001). Our studies have demonstrated that the frequency of G allele in MDM2 promoter 309 increased from LSIL to HSIL and that there was an increased OR for G allele in HSIL cases with high-risk HPV types including 52 and 58. It is known that geographically different oncogenic HPV types 52 and 58 are more prevalent than 16 and 18 in a Japanese population.

Keywords

p53, MDM2, Polymorphism, HPV, Cervical Carcinogenesis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	zur Hausen, H. (2000) Papillomaviruses Causing Cancer: Evasion from Host-Cell Control in Early Events in Carcinogenesis. Journal of the National Cancer Institute, 92, 690-698. http://dx.doi.org/10.1093/jnci/92.9.690
[2]	Ueda, M., Hung, Y.C., Terai, Y., et al. (2003) Glutathione S-Transferase GSTM1, GSTT1 and p53 Codon 72 Polymorphisms in Human Tumor Cells. Human Cell, 16, 241-251. http://dx.doi.org/10.1111/j.1749-0774.2003.tb00158.x
[3]	Ueda, M., Toji, E., Nunobiki, O., et al. (2008) Germline Polymorphism of Cancer Susceptibility Genes in Gynecologic Cancer. Human Cell, 21, 95-104. http://dx.doi.org/10.1111/j.1749-0774.2008.00058.x
[4]	Kubbutat, M.H., Jones, S.N. and Vousden, K.H. (1997) Regulation of p53 Stability by Mdm2. Nature, 387, 299-303. http://dx.doi.org/10.1038/387299a0
[5]	Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 Promotes the Rapid Degradation of p53. Nature, 387, 296-299. http://dx.doi.org/10.1038/387296a0
[6]	Michael, D. and Oren, M. (2002) The p53 and Mdm2 Families in Cancer. Current Opinion in Genetics & Development, 12, 53-59. http://dx.doi.org/10.1016/S0959-437X(01)00264-7
[7]	Moll, U.M. and Petrenko, O. (2003) The MDM2-p53 Interaction. Molecular Cancer Research, 1, 1001-1008.
[8]	Storey, A., Thomas, M., Kalita, A., et al. (1998) Role of a p53 Polymorphism in the Development of Human Papillomavirus Associated Cancer. Nature, 393, 229-234. http://dx.doi.org/10.1038/30400
[9]	Bond, G.L., Hu, W., Bond, E.E., et al. (2004) A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. Cell, 119, 591-602. http://dx.doi.org/10.1016/j.cell.2004.11.022
[10]	Menin, C., Scaini, M.C., De Salvo, G.L., et al. (2006) Association between MDM2-SNP309 and Age at Colorectal Cancer Diagnosis According to p53 Mutation Status. Journal of the National Cancer Institute, 98, 285-288. http://dx.doi.org/10.1093/jnci/djj054
[11]	Dharel, N., Kato, N., Muroyama, R., et al. (2006) MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C. Clinical Cancer Research, 12, 4867-4871. http://dx.doi.org/10.1158/1078-0432.CCR-06-0111
[12]	Lum, S.S., Chua, H.W., Li, H., et al. (2008) MDM2 SNP309 G Allele Increases Risk but the T Allele Is Associated with Earlier Onset Age of Sporadic Breast Cancers in the Chinese Population. Carcinogenesis, 29, 754-761. http://dx.doi.org/10.1093/carcin/bgn024
[13]	Buchynska, L.G., Nesina, I.P. and Kashuba, E.V. (2007) Different Trends of p53, MDM2 and p14 ARF Expression Patterns in Endometrial Adenocarcinomas versus Hyperplasia. Experimental Oncology, 29, 287-294.
[14]	Horree, N., van Diest, P.J., van der Groep, P., Sie-Go, D.M. and Heintz, A.P. (2008) Progressive Derailment of Cell Cycle Regulators in Endometrial Carcinogenesis. Journal of Clinical Pathology, 61, 36-42. http://dx.doi.org/10.1136/jcp.2006.043794
[15]	Meissner Rde, V., Barbosa, R.N., Fernandes, J.V., Galvao, T.M., Galvao, A.F. and Oliveira, G.H. (2007) No Association between SNP309 Promoter Polymorphism in the MDM2 and Cervical Cancer in a Study from Northeastern Brazil. Cancer Detection and Prevention, 31, 371-374. http://dx.doi.org/10.1016/j.cdp.2007.09.001
[16]	Nagano, H., Yoshikawa, H., Kawana, T., Yokota, H., Taketani, Y., Igarashi, H., Yoshikura, H. and Iwamoto, A. (1996) Association of Multiple Human Papillomavirus Types with Vulvar Neoplasias. Journal of Obstetrics and Gynaecology Research, 22, 1-8. http://dx.doi.org/10.1111/j.1447-0756.1996.tb00927.x
[17]	Yoshikawa, H., Kawana, T., Kitagawa, K., Mizuno, M., Yoshikura, H. and Iwamoto, A. (1991) Detection and Typing of Multiple Genital Human Papillomaviruses by DNA Amplification with Consensus Primers. Japanese Journal of Cancer Research, 82, 524-531. http://dx.doi.org/10.1111/j.1349-7006.1991.tb01882.x
[18]	Arvanitis, D.A. and Spandidos, D.A. (2008) Deregulation of the G1/S Phase Transition in Cancer and Squamous Intraepithelial Lesions of the Uterine Cervix: A Case Control Study. Oncology Reports, 204, 751-760.
[19]	Cristina Mazon, R., Rovigatti Gerbelli, T., Benatti Neto, C., de Oliveira, M.R., Antonio Donadi, E., Guimaraes Goncalves, M.A., Garcia Soares, E., Patricia Klay, C., Tersariol, I., Aparecida Pinhal, M., Resende, L. and Pienna Soares, C. (2009) Abnormal Cell-Cycle Expression of the Proteins p27, mdm2 and Cathepsin B in Oral Squamous-Cell Carcinoma Infected with Human Papillomavirus. Acta Histochemica, 113, 109-116. http://dx.doi.org/10.1016/j.acthis.2009.08.008
[20]	Cescon, D.W., Bradbury, P.A., Asomaning, K., Hopkins, J., Zhai, R., Zhou, W., Wang, Z., Kulke, M., Su, L., Ma, C., Xu, W., Marshall, A.L., Heist, R.S., Wain, J.C., Lynch Jr., T.J., Christiani, D.C. and Liu, G. (2009) p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis. Clinical Cancer Research, 15, 3103-3109. http://dx.doi.org/10.1158/1078-0432.CCR-08-3120
[21]	Singhal, P., Hussain, S., Thakur, N., Batra, S., Salhan, S., Bhambani, S. and Bharadwaj, M. (2013) Association of MDM2 and p53 Polymorphisms with the Advancement of Cervical Carcinoma. DNA and Cell Biology, 32, 19-27. http://dx.doi.org/10.1089/dna.2012.1718
[22]	Nunobiki, O., Ueda, M., Yamamoto, M., Toji, E., Sato, N., Izuma, S., Okamoto, Y., Torii, K. and Noda, S. (2010) MDM2 SNP 309 Human Papillomavirus Infection in Cervical Carcinogenesis. Gynecologic Oncology, 118, 258-261. http://dx.doi.org/10.1016/j.ygyno.2010.05.009
[23]	Takehara, K., Toda, T., Nishimura, T., Sakane, J., Kawakami, Y., Mizunoe, T., Nishiwaki, M. and Taniyama, K. (2011) Human Papillomavirus Types 52 and 58 Are Prevalent in Uterine Cervical Squamous Lesions from Japanese Women. Pathology Research International, 2011, Article ID: 246936.